Regenxbio (RGNX) Consolidated Net Income (2014 - 2026)

Regenxbio's Consolidated Net Income history runs 12 years deep, the most recent figure standing at $89.8 million for Q4 2025.

• In Q4 2025, Consolidated Net Income rose 234.83% year-over-year to $89.8 million; the TTM figure through Dec 2025 stood at -$43.0 million (up 83.11% YoY), while the FY2025 annual figure was -$535.6 million, down 132.24% from the prior year.
• Consolidated Net Income for Q4 2025 stood at $89.8 million, up from -$65.5 million in the prior quarter.
• The five-year high for Consolidated Net Income was $294.0 million in Q4 2021, with the low at -$76.7 million in Q1 2022.
• The 5-year median for Consolidated Net Income is -$62.4 million (2023), against an average of -$18.7 million.
• Peak annual rise in Consolidated Net Income reached 735.85% in 2021, while the deepest fall reached 764.37% in 2021.
• Regenxbio's Consolidated Net Income stood at $294.0 million in 2021, then declined by 5.04% to $279.2 million in 2022, then sank by 122.55% to -$63.0 million in 2023, then retreated by 5.8% to -$66.6 million in 2024, then jumped by 234.83% to $89.8 million in 2025.
• Business Quant data shows RGNX's Consolidated Net Income at $89.8 million in Q4 2025, -$65.5 million in Q3 2025, and -$70.9 million in Q2 2025.